Literature DB >> 19343717

A proteomic-based approach for the identification of immunodominant Cryptococcus neoformans proteins.

Mattie Young1, Sandra Macias, Derek Thomas, Floyd L Wormley.   

Abstract

Cryptococcus neoformans is an opportunistic fungal pathogen that can cause life-threatening meningoencephalitis in immune compromised patients. Previous, studies in our laboratory have shown that prior exposure to an IFN-gamma-producing C. neoformans strain (H99gamma) elicits protective immunity against a second pulmonary C. neoformans challenge. Here, we characterized the antibody response produced in mice protected against experimental pulmonary C. neoformans infection compared to nonprotected mice. Moreover, we evaluated the efficacy of using serum antibody from protected mice to detect immunodominant C. neoformans proteins. Protected mice were shown to produce significantly more C. neoformans-specific antibodies following a second experimental pulmonary cryptococcal challenge compared to nonprotected mice. Immunoblot analysis of C. neoformans proteins resolved by 2-DE using serum from nonprotected mice failed to show any reactivity. In contrast, serum from protected mice was reactive with several cryptococcal protein spots. Analysis of these spots by capillary HPLC-ESI-MS/MS identified several cryptococcal proteins shown to be associated with the pathogenesis of cryptococcosis. Our studies demonstrate that mice immunized with C. neoformans strain H99gamma produce antibodies that are immune reactive against specific cryptococcal proteins that may provide a basis for the development of immune based therapies that induce protective anticryptococcal immune responses.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19343717      PMCID: PMC2754056          DOI: 10.1002/pmic.200800713

Source DB:  PubMed          Journal:  Proteomics        ISSN: 1615-9853            Impact factor:   3.984


  79 in total

Review 1.  The molecular basis for the immunogenicity of Cryptococcus neoformans mannoproteins.

Authors:  Stuart M Levitz; Charles A Specht
Journal:  FEMS Yeast Res       Date:  2006-06       Impact factor: 2.796

Review 2.  14-3-3 proteins in cell cycle regulation.

Authors:  Heiko Hermeking; Anne Benzinger
Journal:  Semin Cancer Biol       Date:  2006-04-01       Impact factor: 15.707

3.  Human immunoglobulin G2 (IgG2) and IgG4, but not IgG1 or IgG3, protect mice against Cryptococcus neoformans infection.

Authors:  David O Beenhouwer; Esther M Yoo; Chun-Wei Lai; Miguel A Rocha; Sherie L Morrison
Journal:  Infect Immun       Date:  2007-01-12       Impact factor: 3.441

4.  Cerebrospinal fluid 14-3-3-gamma protein level in eight HIV-negative cryptococcal meningitis adults.

Authors:  W N Chang; C H Lu; C R Huang; Y C Chuang; N W Tsai; S F Chen; C C Chang; H C Wang
Journal:  Eur J Neurol       Date:  2008-02-16       Impact factor: 6.089

Review 5.  Antibody-mediated protection through cross-reactivity introduces a fungal heresy into immunological dogma.

Authors:  Arturo Casadevall; Liise-anne Pirofski
Journal:  Infect Immun       Date:  2007-08-20       Impact factor: 3.441

6.  Protection against cryptococcosis by using a murine gamma interferon-producing Cryptococcus neoformans strain.

Authors:  Floyd L Wormley; John R Perfect; Chad Steele; Gary M Cox
Journal:  Infect Immun       Date:  2007-01-08       Impact factor: 3.441

7.  A proteomic-based approach for the identification of Candida albicans protein components present in a subunit vaccine that protects against disseminated candidiasis.

Authors:  Derek P Thomas; Angel Viudes; Carlos Monteagudo; Anna L Lazzell; Stephen P Saville; Jose L López-Ribot
Journal:  Proteomics       Date:  2006-11       Impact factor: 3.984

8.  Proteomics for the analysis of the Candida albicans biofilm lifestyle.

Authors:  Derek P Thomas; Stefano P Bachmann; Jose L Lopez-Ribot
Journal:  Proteomics       Date:  2006-11       Impact factor: 3.984

9.  Extracellular vesicles produced by Cryptococcus neoformans contain protein components associated with virulence.

Authors:  Marcio L Rodrigues; Ernesto S Nakayasu; Debora L Oliveira; Leonardo Nimrichter; Joshua D Nosanchuk; Igor C Almeida; Arturo Casadevall
Journal:  Eukaryot Cell       Date:  2007-11-26

10.  Direct inhibition of T-cell responses by the Cryptococcus capsular polysaccharide glucuronoxylomannan.

Authors:  Lauren E Yauch; Jennifer S Lam; Stuart M Levitz
Journal:  PLoS Pathog       Date:  2006-11       Impact factor: 6.823

View more
  20 in total

1.  Interleukin-17 is not required for classical macrophage activation in a pulmonary mouse model of Cryptococcus neoformans infection.

Authors:  Sarah E Hardison; Karen L Wozniak; Jay K Kolls; Floyd L Wormley
Journal:  Infect Immun       Date:  2010-10-04       Impact factor: 3.441

2.  Identification and characterization of Cryptococcus neoformans protein fractions that induce protective immune responses.

Authors:  Ashok K Chaturvedi; Susan T Weintraub; Jose L Lopez-Ribot; Floyd L Wormley
Journal:  Proteomics       Date:  2013-12       Impact factor: 3.984

3.  Cryptococcus strains with different pathogenic potentials have diverse protein secretomes.

Authors:  Leona T Campbell; Anna R Simonin; Cuilan Chen; Jannatul Ferdous; Matthew P Padula; Elizabeth Harry; Markus Hofer; Iain L Campbell; Dee A Carter
Journal:  Eukaryot Cell       Date:  2015-04-03

4.  Cryptococcal heat shock protein 70 homolog Ssa1 contributes to pulmonary expansion of Cryptococcus neoformans during the afferent phase of the immune response by promoting macrophage M2 polarization.

Authors:  Alison J Eastman; Xiumiao He; Yafeng Qiu; Michael J Davis; Priya Vedula; Daniel M Lyons; Yoon-Dong Park; Sarah E Hardison; Antoni N Malachowski; John J Osterholzer; Floyd L Wormley; Peter R Williamson; Michal A Olszewski
Journal:  J Immunol       Date:  2015-05-13       Impact factor: 5.422

5.  Protection of mice against experimental cryptococcosis using glucan particle-based vaccines containing novel recombinant antigens.

Authors:  Maureen M Hester; Chrono K Lee; Ambily Abraham; Payam Khoshkenar; Gary R Ostroff; Stuart M Levitz; Charles A Specht
Journal:  Vaccine       Date:  2019-11-04       Impact factor: 3.641

6.  Pulmonary infection with an interferon-gamma-producing Cryptococcus neoformans strain results in classical macrophage activation and protection.

Authors:  Sarah E Hardison; Sailatha Ravi; Karen L Wozniak; Mattie L Young; Michal A Olszewski; Floyd L Wormley
Journal:  Am J Pathol       Date:  2010-01-07       Impact factor: 4.307

Review 7.  A Call to Arms: Quest for a Cryptococcal Vaccine.

Authors:  Marley C Caballero Van Dyke; Floyd L Wormley
Journal:  Trends Microbiol       Date:  2017-11-02       Impact factor: 17.079

8.  Role of IL-17A on resolution of pulmonary C. neoformans infection.

Authors:  Karen L Wozniak; Sarah E Hardison; Jay K Kolls; Floyd L Wormley
Journal:  PLoS One       Date:  2011-02-17       Impact factor: 3.240

9.  Insights into the mechanisms of protective immunity against Cryptococcus neoformans infection using a mouse model of pulmonary cryptococcosis.

Authors:  Karen L Wozniak; Sailatha Ravi; Sandra Macias; Mattie L Young; Michal A Olszewski; Chad Steele; Floyd L Wormley
Journal:  PLoS One       Date:  2009-09-03       Impact factor: 3.240

10.  Depletion of neutrophils in a protective model of pulmonary cryptococcosis results in increased IL-17A production by γδ T cells.

Authors:  Karen L Wozniak; Jay K Kolls; Floyd L Wormley
Journal:  BMC Immunol       Date:  2012-12-07       Impact factor: 3.615

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.